News

Aspen's target is financially small today but creates an early map for GLP-1 expansion across Africa.

Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre

There is no end in sight for the company's incredible momentum.

Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.

Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Merida's lead autoimmune and allergy candidate is in Phase 1 and is expected to support Lilly's move beyond its established focus on diabetes and obesity therapies. For readers looking to explore more...

Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.

A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.

Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.

PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

Novo Nordisk A/S (NYSE:NVO) has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available. Germany is the EU’s largest pharmaceutical market, so the launch is an important step for Novo as it works to strengthen its position in the […]

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...

The drug giant added to its immunotherapy portfolio.

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

Management's story has pivoted from concrete wins today to a distant, AI-powered future, a move that coincides with declining revenue in its core business.

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.

AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.

Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.

Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.

The high-flying healthcare leader looks unstoppable right now.

Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.

LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.

Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.

GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

The milestone-heavy purchase adds a broad scientific platform, but its lead medicine remains at the earliest clinical stage.

Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026. The acquisition expands Lilly’s immunology pipeline and gives it access to Merida’s antibody-engineering platform, which is […]